OCUGEN, INC. Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit
OCUGEN, INC. (OCGN) reported Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit of $9.97 per share for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-22.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit · last filed 2019-03-22
- OCUGEN, INC. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2018 was $9.97.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 9 month | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 12 month |
|---|---|---|
| 2018-12-31 | $9.97 10-K · filed 2019-03-22 | |
| 2018-09-30 | $9.97 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |